Evolution of diabetes management in the 21st century: The contribution of quality of life measurement in Asians

Asia Pacific Journal of Clinical Nutrition

Volumn 24, Issue 2, 2015, Pages 190-198

  Goh, Shereen Giap Kah ^a   Rusli, Bin Nordin ^a   Khalid, Bin Abdul Kadir ^a  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

Asians; Diabetes mellitus; Quality of life

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

ASIA; COST OF ILLNESS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEEDING BEHAVIOR; FEMALE; HEALTH CARE COST; HEALTH STATUS; HUMAN; MALE; PATHOPHYSIOLOGY; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SOCIOECONOMICS;

ASIA; COST OF ILLNESS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEEDING BEHAVIOR; FEMALE; FOOD HABITS; HEALTH EXPENDITURES; HEALTH STATUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; QUALITY OF LIFE; QUESTIONNAIRES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SOCIOECONOMIC FACTORS;

EID: 84931066943     PISSN: 09647058     EISSN: None     Source Type: Journal    
DOI: 10.6133/apjcn.2015.24.2.04     Document Type: Review

References (80)

1. Spijkerman AMW, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D, Stehouwer CDA, Bouter LM, Heine RJ. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn screening study. Diabetes Care. 2003;26:2604-8. doi: 10.2337/diacare.26.9.2604.
2. Spijkerman AMW, Henry RMA, Dekker JM, Nijpels G, Kostense PJ, Kors JA, Ruwaard D, Stehouwer CDA, Bouter LM, Heine RJ. Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study. J Intern Med. 2004;256:429-36. doi: 10.1111/j.1365-2796.2004.01395.x.
3. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF Consultation. Geneva: WHO; 2006.
4. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2012;35:S11-63.
5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian diabetes association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32:S95-8.
6. Colagiuri S, Dickinson S, Girgis S. National evidence based guideline for blood glucose control in type 2 diabetes. Canberra: Diabetes Australia and the NHMRC; 2009.
7. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guidelines 87. London: Royal College of Physicians; 2009.
8. UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352: 837-53. doi: 10.1016/S0140-6736(98)07019-6.
9. Stratton IM. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35): prospective observational study. BMJ. 2000; 321:405-12. doi: 10.1136/bmj.321.7258.405.
10. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: a randomized prospec-tive 6-year study. Diabetes Res Clin Pract. 1995;28:103-17. doi: 10.1016/0168-8227(95)01064-K.
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86. doi: 10.1056/NEJM199309303291401.
12. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53.
13. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59. doi: 10.1056/NE JMoa0802743.
14. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohenet RM et al. the ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419-30. doi: 10.1016/S014 0-6736(10)60576-4.
15. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72. doi: 10.1016/j. jvn.2008.08.002.
16. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. the VADT investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39. doi: 10.1056/NEJMoa0808 431.
17. U.K. Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22:1125-36. doi: 10.2337/diacare.22.7.1125.
18. Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care. 1997; 20:562-7. doi: 10.2337/diacare.20.4.562.
19. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002;25:458-63. doi: 10.2337/dia care.25.3.458.
20. United Nations. Classification of countries by major area and region of the world, 2012. Available from: http://www.esa.un.org/wpp/exel-Data/country-Classification.pdf.
21. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-21. doi: 10. 1016/j.diabres.2011.10.029.
22. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53. doi: 10. 2337/diacare.27.5.1047.
23. Chan J, Malik V, Jia W. Diabetes in Asia. JAMA. 2009;301: 2129-40. doi: 10.1001/jama.2009.726.
24. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:293-301. doi: 10.1016/j.diabres.2010.12.025.
25. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010;375:408-18. doi: 10.1016/S0140-6736(09)6093 7-5.
26. Mohan V, Ramachandran A, Snehalatha C, Mohan R, Viswanathan M. High prevalence of maturity onset diabetes of the young in S. India. Diabetes Care. 1985;8:371-4. doi: 10.2337/diacare.8.4.371.
27. Ng MCY, Lee SC, Ko GTC, Li JKY, So WY, Hashim Y et al. Familial early-onset type 2 diabetes in Chinese patients: obesity and genetics have more significant roles than autoimmunity. Diabetes Care. 2001;24:663-71. doi: 10.2337/dia care.24.4.663.
28. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681-8. doi: 10.1016/S0140-6736 (06)69703-1.
29. Hu FB. Globalization of diabetes. Diabetes Care. 2011;34: 1249-57. doi: 10.1016/S0140-6736(06)69703-1.
30. WHOQOL SRPB Group. A cross-cultural study of spirituality, religion, and personal beliefs as components of quality of life. Soc Sci Med. 2006;62:1486-97. doi: 10.1016/j. socscimed.2005.08.001.
31. Guarnnaccia. Anthropological perspectives: the importance of culture in the assessment of Quality of Life. In Quality of Life and pharmacoeconomics in clinical trials. Philadelphia: Lipincott-Raven; 1996. pp. 523-7.
32. World Health Organization. WHOQOL: measuring quality of life, world health organization: division of mental health and prevention of substance abuse. Geneva: WHO; 1997.
33. Read JL. The new era in quality of life assessment. In Quality of Life Assessment: key issues in the 1990's. Netherlands: Springer; 1993. pp. 3-10. doi: 10.1007/978-94-011-2988-6_1.
34. Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health. 2001;4:392-400. doi: 10.1046/j.1524-4733.2001.45029.x.
35. Brown GC, Brown MM, Sharma S, Brown H, Gosum M, Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14:18-24. doi: 10.1016/S1056-8727(00)00061-1.
36. Glasgow RE. Behavioural and psychosocial measures for diabetes care. What is important to assess?. Diabetes Spectrum. 1997;10:12-7.
37. Glasgow R, Osteen V. Evaluating diabetes education: are we measuring the most important outcomes?. Diabetes Care. 1992;15:1423-32. doi: 10.2337/diacare.15.10.1423.
38. Salant T, Lauderdale DS. Measuring culture: a critical review of acculturation and health in Asian immigrant populations. Soc Sci Med. 2003;57:71-90. doi: 10.1016/S0277-95 36(02)00300-3.
39. Fujimoto WY. The growing prevalence of non-insulindependent diabetes in migrant Asian populations and its implicat ions for Asia. Diabetes Res Clin Prac. 1992;15:167-84. doi: 10.1016/0168-8227(92)90022-J.
40. Cheung Y.B, Thumboo J. Development of health-related quality of life instruments for use in Asia: the issues. Pharmaco Economics. 2006;24:643-50. doi: 10.2165/00019053-200624070-00003.
41. Carey MP, Jorgensen RS, Weinstock RS, Sprafkin RP, Lantinga LJ, Carnrike CL et al. Reliability and validity of the appraisal of diabetes scale. J Behav Med. 1991;14:43-51. doi: 10.1007/BF00844767.
42. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res. 1999;8:79-91. doi: 10.1023/A:1026485130100.
43. Meadows K, Steen N, McColl E, Eccles M, Shiels C, Hewison J et al. The Diabetes Health Profile (DHP): a new instrument for assessing the psychosocial profile of insulin requiring patients-development and psychometric evaluation. Qual Life Res. 1996;5:242-54. doi: 10.1007/BF004347 46.
44. Hammond GS, Aoki TT. Measurement of health status in diabetic patients. Diabetes impact measurement scales. Diabetes Care. 1992;15:469-77. doi: 10.2337/diacare.15.4.469.
45. DCCT Research Group. Reliability and validity of a diabetes quality-of-life measure for the Diabetes Control and Complications Trial (DCCT). Diabetes Care. 1988;11:725-32. doi: 10.2337/diacare.11.9.725.
46. Boyer JG, Earp JAL, Care SM, May N, Earp JOAL, Carolina N et al. The development of an instrument for assessing quality of life of people with diabetes: diabetes 39. Med Care. 1997;35:440-53.
47. Bott U, Mühlhauser I, Overmann H, Berger M. Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes. Diabetes Care. 1998;21:757-69.
48. Herschbach P, Duran G, Waadt S, Zettler A, Amm C, Marten-Mittag B. Psychometric properties of the Questionnaire on Stress in Patients with Diabetes-Revised (QSD-R). Health Psychol. 1997;16:171-4. doi: 10.1037//0278-6133.16. 2.171.
49. Mannucci E, Ricca V, Bardini GRC. Well-being enquiry for diabetics: a new measure of diabetes-related quality of life. Diabetes Nutr Metab Clin Exp. 1996;9:89-102.
50. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care. 1992;30:473-83.
51. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL Group. Qual Life Res. 2004;13:299-310. doi: 10.1023/B:QURE.0000018486.9136 0.00.
52. Garratt AM, Schmidt L, Fitzpatrick R. Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med. 2002;19:1-11. doi: 10.1046/j.1464-5491.2002.0 0650.x.
53. Hunt S.M. Cross-cultural comparability of quality of life measures. Drug Inform J. 1993;27:395-400. doi: 10.1177/00 9286159302700223.
54. The Euroqol Group. Euroqol-a new facility for the measurement of health related quality-of-life. Health Policy. 1990;16:199-208. doi: 10.1016/0168-8510(90)90421-9.
55. Bowden A, Fox-Rushby JA. A systematic and critical review of the process of translation and adaptation of generic health-related quality of life measures in Africa, Asia, Eastern Europe, the Middle East, South America. Soc Sci Med. 2003;57:1289-306. doi: 10.1016/S0277-9536(02)00503-8.
56. Cheng AY, Tsui EY, Hanley AJ, Zinman B. Developing a quality of life measure for Chinese patients with diabetes. Diabetes Res Clin Pract. 1999;46:259-67. doi: 10.1016/S016 8-8227(99)00091-1.
57. Wee HL, Li S-C, Cheung YB, Fong KY, Thumboo J. The influence of ethnicity on health-related quality of life in diabetes mellitus: a population-based, multiethnic study. J Diabetes Complications. 2006;20:170-8. doi: 10.1016/j.jdiacom p.2005.06.010.
58. Lau A, Chi I, McKenna K. Self-perceived quality of life of Chinese elderly people in Hong Kong. Occup Ther Int. 1998; 5:118-39. doi: 10.1002/oti.71.
59. Thumboo J, Fong KY, Chan SP. The equivalence of English and Chinese SF-36 versions in bilingual Singapore Chinese. Qual Life Res. 2002;11:495-503.
60. Glasziou P, Alexander J, Beller E, Clarke P. The ADVANCE Collaborative Group: which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes. 2007;5:1-11. doi: 10.1186/1477-7525-5-21.
61. Boonen A, van der HD, Landewe R, van TA, Mielants H, Dougados M et al. How do the EQ-5D, SF-6D and the wellbeing rating scale compare in patients with ankylosing spondylitis?. Ann Rheum Dis. 2007;66:771-7. doi: 10.1136/ard.2006.060384.
62. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13:873-84. doi: 10.1002/hec.866.
63. Brazier J, Jones N, Kind P. Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire. Qual Life Res. 1993;2:169-80. doi: 10.1007/BF00 435221.
64. Ellis JJ, Eagle KA, Kline-Rogers EM, Erickson SR. Validation of the EQ-5D in patients with a history of acute coronary syndrome. Curr Med Res Opin. 2005;21:1209-16. doi: 10.1185/030079905X56349.
65. Dolan P. Modelling valuation for Euroqol health states. Med Care. 1997;35:351-63. doi: 10.1097/00005650199711000-00002.
66. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736-41. doi: 10.1136/bmj.316.7133.736.
67. Barton G, Sach T, Doherty M, Avery A, Jenkinson C, Muir K. An assessment of the discriminative ability of the EQ-5D index, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. Eur J Health Econ. 2008;9:237-49. doi: 10.1007/s10198-007-0068-z.
68. Jacobson AM, De Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type 1 and type 2 diabetes. Diabetes Care. 1994;17:267-74. doi: 10.233 7/diacare.17.4.267.
69. Shen W, Kotsanos JG, Huster WJ, Mathias SD, Andrejasich CM, Patrick DL. Development and validation of the diabetes quality of life clinical trial questionnaire. Med Care. 1999;37: AS45-66. doi: 10.1097/00005650-199904001-00008.
70. Lawton J, Ahmad N, Hanna L, Douglas M, Bains H, Hallowell N. 'We should change ourselves, but we can't': accounts of food and eating practices amongst British Pakistanis and Indians with type 2 diabetes. Ethn Health. 2008; 13:305-19. doi: 10.1080/13557850701882910.
71. Wahlqvist ML. Asian migration to Australia: food and health consequences. Asia Pac J Clin Nutr. 2002;11:S562-8. doi: 10.1046/j.1440-6047.11.supp3.13.x.
72. van Doorslaer E, O'Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR, Garg CC et al. Catastrophic payments for health care in Asia. Health Econ. 2007;16:1159-84. doi: 10.1002/hec.1209.
73. Benbow SJ, Wallymahmed ME, Macfarlane IA. Diabetic peripheral neuropathy and quality of life. QJM. 1998;91: 733-7. doi: 10.1093/qjmed/91.11.733.
74. Robert D Goldney, Pat J Philips, Laura J Fisher, David H. Wilson. Diabetes, depression, and quality of life. Diabetes Care. 2004;27:1066-70. doi: 10.2337/diacare.27.5.1066.
75. Gonzalez JS, Safren SA, Delahanty LM, Cagliero E, Wexler DJ, Meigs JB, Grant RW. Symptoms of depression prospectively predict poorer self-care in patients with type 2 diabetes. Diabet Med. 2008;25:1102-7. doi: 10.1111/j.1464-5491.2008.02535.x.
76. Egede LE. Diabetes, major depression, and functional disability among U.S. adults. Diabetes Care. 2004;27:421-8. doi: 10.2337/diacare.27.2.421.
77. Lauber C, Rossler W. Stigma towards people with mental illness in developing countries in Asia. Int Rev Psychiatry. 2007;19:157-78. doi: 10.1080/09540260701278903.
78. Siu SC, Lo SK, Wong KW, Ip KM, Wong YS. Prevalence of and risk factors for erectile dysfunction in Hong Kong diabetic patients. Diabet Med. 2001;18:732-8. doi: 10.1046/j. 0742-3071.2001.00557.x.
79. Hisasue S, Kumamoto Y, Sato Y, Masumori N, Horita H, Kato R, Kobayashi K, Hashimoto K, Yamashita N, Itoh N. Prevalence of female sexual dysfunction symptoms and its relationship to quality of life: a Japanese female cohort study. Urology. 2005;65:143-8. doi: 10.1016/j.urology.2004.08.00 3.
80. Nicolosi A, Glasser DB, Kim SC, Marumo K, Laumann EO. GSSAB Investigators' Group. Sexual behaviour and dysfunction and help-seeking patterns in adults aged 40-80 years in the urban population of Asian countries. BJU Int. 2005;95:609-14. doi: 10.1111/j.1464-410X.2005.05348.x.